SCHEMBL6475465

SCHEMBL6475465

CC(CNS(=O)(=O)C(C)C)Oc1ccc(-c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 1/20 0.48
KCNH2 Q12809 1/20 0.48
PLAU P00749 2/20 0.45
PLAT P00750 2/20 0.45
GRIA4 P48058 3/20 0.44
ADAMTS4 O75173 2/20 0.43
MMP13 P45452 2/20 0.43
NR1D1 P20393 1/20 0.41
PLG P00747 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
KIF11 P52732 2/20 0.40
GPR34 Q9UPC5 1/20 0.39
MAOB P27338 1/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
ADRA2C P18825 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474222 0.88 KIF11 (0.44) GRIA2KCNH2GRIA4ADAMTS4MMP13
SCHEMBL6475469 0.86 PLAU (0.43) GRIA2KCNH2PLAUPLATGRIA4
SCHEMBL6479537 0.85 GRIA4 (0.47) GRIA2GRIA4ADAMTS4MMP13NR1D1
SCHEMBL6474044 0.83 GRIA4 (0.48) GRIA2GRIA4MMP13NR1D1
SCHEMBL6475291 0.83 GRIA4 (0.62) GRIA2GRIA4MAPTCYP1A2CYP2C19
SCHEMBL6482318 0.83 GRIA4 (0.53) GRIA2GRIA4MAPTCYP1A2CYP2C19
SCHEMBL6474261 0.82 GRIA4 (0.47) GRIA2GRIA4ADAMTS4MMP13
SCHEMBL6474424 0.82 GRIA4 (0.49) GRIA2PLAUGRIA4
SCHEMBL6474213 0.82 MTNR1A (0.48) PLAUGRIA4NR1D1MAOB
SCHEMBL5878298 0.82 GRIA4 (0.67) GRIA2KCNH2PLAUPLATGRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA2 3/4885KCNH2 917/4885PLAU 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.